February 6, 2019

The Early Diagnosis of Alzheimer’s Disease: Overcoming the Obstacles

International Conference on Alzheimer’s and Parkinson’s Disease 2020

Exploring Imaging Biomarkers in the Diagnosis of Alzheimer’s Disease across the Age Span

Tammie Benzinger, MD, PhD, discusses the use of imaging biomarkers in the diagnosis of Alzheimer’s disease across the age span, with discussion on how these imaging biomarkers differ in early-onset compared with late-onset Alzheimer’s disease. She discusses the imaging biomarker results in the patient case study, as well as highlighting some of the system constraints involved in imaging in Alzheimer’s disease. Philip Scheltens then discusses the MRI results in the patient case study, alongside additional assessments including genetic screening, PET imaging, and CSF biomarkers.

Key Learning Objectives for Biogen’s AAT-AD/PD 2020 Symposium:

  • Understand the importance of an early diagnosis of Alzheimer’s disease
  • Assess the current healthcare system readiness for a paradigm shift to early diagnosis
  • Gain insights on how cognitive assessment tools and imaging biomarkers can be used to distinguish between different subtypes of Alzheimer’s disease
  • Increase understanding of the differences between the pathology of familial or sporadic early-onset and late-onset Alzheimer’s disease

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.